Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Ti-Ventures SA is a seed investment fund founded in 2016 and located in southern Switzerland. Owned by the Fondazione Centenario Banca Stato, it focuses on early-stage companies with innovative technologies. The fund primarily operates in the life sciences, medical technology, high-tech, and IT sectors.
Ti-Ventures invests in early-stage companies in Ticino, Switzerland, with a focus on life sciences, medical technology, high-tech, and IT. The fund typically engages in pre-seed, seed, and Series A rounds, supporting companies that demonstrate high growth potential. Collaborations with local universities and government entities enhance their investment strategy.
Ti-Ventures has backed notable companies such as Gain Therapeutics, which went public on NASDAQ in 2021, and Sailogy, which successfully exited in 2018. Other portfolio companies include Delvitech SA, which received seed funding in 2018 and participated in a Series A round in 2020, and xFarm, which has undergone multiple funding rounds, including a Series B in 2022 and plans for a Series C in 2024. BigOmics Analytics also received seed investment in 2021 and participated in a Series A round in 2022.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.